AAAAAA
Results:
1-14
|
Results: 14
Authors:
SPAHNLANGGUTH H
BAKTIR G
RADSCHUWEIT A
OKYAR A
TERHAAG B
ADER P
HANAFY A
LANGGUTH P
Citation: H. Spahnlangguth et al., P-GLYCOPROTEIN TRANSPORTERS AND THE GASTROINTESTINAL-TRACT - EVALUATION OF THE POTENTIAL IN-VIVO RELEVANCE OF IN-VITRO DATA EMPLOYING TALINOLOL AS MODEL-COMPOUND, International journal of clinical pharmacology and therapeutics, 36(1), 1998, pp. 16-24
Authors:
WEIGMANN I
TERHAAG B
WIERICH W
HERRMANN WM
Citation: I. Weigmann et al., ANTIHYPERTENSIVE EFFECTS OF DIFFERENT TAL INOLOL DOSAGES AFTER 4 WEEKS OF TREATMENT IN COMPARISON WITH PLACEBO, Arzneimittel-Forschung, 48(3), 1998, pp. 240-244
Authors:
HOFFMANN C
ZSCHIESCHE M
FRANKE G
HOFFMANN A
TERHAAG B
MORITZ KU
SIEGMUND W
Citation: C. Hoffmann et al., A SINGLE AND MULTIPLE-DOSE BIOAVAILABILITY STUDY WITH CARBAMAZEPINE 400 MG RETARD TABLETS WITH REFERENCE TO ENZYME AUTOINDUCTION AND CIRCADIAN TIME DIFFERENCES, International journal of clinical pharmacology and therapeutics, 35(11), 1997, pp. 496-503
Authors:
WETTERICH U
SPAHNLANGGUTH H
MUTSCHLER E
TERHAAG B
ROSCH W
LANGGUTH P
Citation: U. Wetterich et al., EVIDENCE FOR INTESTINAL SECRETION AS AN ADDITIONAL CLEARANCE PATHWAY OF TALINOLOL ENANTIOMERS - CONCENTRATION-DEPENDENT AND DOSE-DEPENDENT ABSORPTION IN-VITRO AND IN-VIVO, Pharmaceutical research, 13(4), 1996, pp. 514-522
Authors:
PECHSTEIN B
HERMANN R
TERHAAG B
Citation: B. Pechstein et al., TOLERABILITY, PHARMACOKINETICS AND DOSE LINEARITY OF D-23129 FOLLOWING ORAL SINGLE-DOSE ESCALATION IN HEALTHY-VOLUNTEERS, Naunyn-Schmiedeberg's archives of pharmacology, 354(4), 1996, pp. 124-124
Authors:
GRAMATTE T
OERTEL R
TERHAAG B
KIRCH W
Citation: T. Gramatte et al., DIRECT DEMONSTRATION OF SMALL-INTESTINAL SECRETION AND SITE-DEPENDENTABSORPTION OF THE BETA-BLOCKER TALINOLOL IN HUMANS, Clinical pharmacology and therapeutics, 59(5), 1996, pp. 541-549
Authors:
BERNDT A
GRAMATTE T
OERTEL R
TERHAAG B
RICHTER K
KIRCH W
Citation: A. Berndt et al., DAY-NIGHT VARIATIONS IN THE RENAL EXCRETION OF THE ANTIARRHYTHMIC AGENT TIRACIZINE AND ITS METABOLITES, Chronobiology international, 12(2), 1995, pp. 135-140
Authors:
DEMEY C
SCHROETER V
BUTZER R
JAHN P
WEISSER K
WETTERICH U
TERHAAG B
MUTSCHLER E
SPAHNLANGGUTH H
PALM D
BELZ GG
Citation: C. Demey et al., DOSE-EFFECT AND KINETIC-DYNAMIC RELATIONSHIPS OF THE BETA-ADRENOCEPTOR BLOCKING PROPERTIES OF VARIOUS DOSES OF TALINOLOL IN HEALTHY HUMANS, Journal of cardiovascular pharmacology, 26(6), 1995, pp. 879-888
Authors:
BERNDT A
OERTEL R
TERHAAG B
RICHTER K
GRAMATTE T
Citation: A. Berndt et al., PHARMACOKINETICS OF THE ANTIARRHYTHMIC AGENT TIRACIZINE - STEADY-STATE KINETICS IN COMPARISON WITH SINGLE-DOSE KINETICS, Biopharmaceutics & drug disposition, 16(5), 1995, pp. 427-441
Authors:
WEIGMANN I
TERHAAG B
HAASE H
SCHNABEL F
Citation: I. Weigmann et al., THERAPY OF ARTERIAL-HYPERTENSION AND CORO NARY HEART-DISEASE WITH THESELECTIVE BETA-1-BLOCKER TALINOLOL, Die medizinische Welt, 46(6), 1995, pp. 341-347
Authors:
TROGER U
MARTENS J
MEYER FP
HOFFMANN A
TERHAAG B
Citation: U. Troger et al., STUDY ON THE BIOEQUIVALENCE OF AN ORAL NIFEDIPINE FORMULATION AND A SUSTAINED-RELEASE REFERENCE PREPARATION AFTER SINGLE-DOSE AND REPEATED DOSES, Arzneimittel-Forschung, 45-2(12), 1995, pp. 1266-1270
Authors:
BERNDT A
OERTEL R
RICHTER K
TERHAAG B
GRAMATTE T
Citation: A. Berndt et al., RELATIVE BIOAVAILABILITY OF THE ANTIARRHY THMIC AGENT TIRACIZINE AND 3 OF ITS METABOLITES, Arzneimittel-Forschung, 45-1(3), 1995, pp. 250-253
Authors:
DOBREV D
BERNDT A
OERTEL R
RICHTER K
TERHAAG B
GRAMATTE T
Citation: D. Dobrev et al., BIOEQUIVALENCE OF METOCLOPRAMIDE IN 2 TAB LET FORMULATIONS, Arzneimittel-Forschung, 45-1(3), 1995, pp. 304-306
Authors:
BERNDT A
GRAMATTE T
OERTEL R
RICHTER K
TERHAAG B
KIRCH W
Citation: A. Berndt et al., DOSE-DEPENDENT TIRACIZINE DISPOSITION IN HEALTHY-VOLUNTEERS - SERUM AND URINE KINETICS AND DOSE-RELATED ECG-CHANGES, European journal of drug metabolism and pharmacokinetics, 19(4), 1994, pp. 359-368
Risultati:
1-14
|